Long-term Efficacy and Safety of Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Prospective European Multinational Observational Study

Background: Evidence for the efficacy of nusinersen in adults with 5q-associated spinal muscular atrophy (SMA) has been demonstrated up to a period of 16 months in relatively large cohorts but whereas patients reach a plateau over time is still to be demonstrated. We investigated the efficacy and safety of nusinersen in adults with SMA over 38 months, the longest time period to date in a large cohort of patients from multiple clinical sites.

Methods: Our prospective, observational study included adult patients with SMA from Germany, Switzerland, and Austria (July 2017 to May 2022). All participants had genetically-confirmed, 5q-associated SMA and were treated with nusinersen according to the label. The total Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM) scores, and 6-min walk test (6 MWT; metres), were recorded at baseline and 14, 26, and 38 months after treatment initiation, and pre and post values were compared. Adverse events were also recorded.

Findings: Overall, 389 patients were screened for eligibility and 237 were included. There were significant increases in all outcome measures compared with baseline, including mean HFMSE scores at 14 months (mean difference 1.72 [95% CI 1.19-2.25]), 26 months (1.20 [95% CI 0.48-1.91]), and 38 months (1.52 [95% CI 0.74-2.30]); mean RULM scores at 14 months (mean difference 0.75 [95% CI 0.43-1.07]), 26 months (mean difference 0.65 [95% CI 0.27-1.03]), and 38 months (mean difference 0.72 [95% CI 0.25-1.18]), and 6 MWT at 14 months (mean difference 30.86 m [95% CI 18.34-43.38]), 26 months (mean difference 29.26 m [95% CI 14.87-43.65]), and 38 months (mean difference 32.20 m [95% CI 10.32-54.09]). No new safety signals were identified.

Interpretation: Our prospective, observational, long-term (38 months) data provides further real-world evidence for the continuous efficacy and safety of nusinersen in a large proportion of adult patients with SMA.

Funding: Financial support for the registry from Biogen, Novartis and Roche.

Citing Articles

Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen.

Cebulla G, Hai L, Warnken U, Gungor C, Hoffmann D, Korporal-Kuhnke M J Neurol. 2025; 272(4):270.

PMID: 40085221 DOI: 10.1007/s00415-025-12984-7.

Extracellular vesicles efficiently deliver survival motor neuron protein to cells in culture.

Rene C, Parks R Sci Rep. 2025; 15(1):5674.

PMID: 39955442 PMC: 11830090. DOI: 10.1038/s41598-025-90083-3.

Long-Term Dynamics of CSF and Serum Neurofilament Light Chain in Adult Patients With 5q Spinal Muscular Atrophy Treated With Nusinersen.

Cordts I, Fuetterer C, Wachinger A, von Heynitz R, Kessler T, Freigang M Neurology. 2025; 104(5):e213371.

PMID: 39946662 PMC: 11837849. DOI: 10.1212/WNL.0000000000213371.

Awareness and care practices for rare neurologic diseases among senior neurologists: A global survey.

Jang D, Federico A, Savelieff M, Grisold W, Mancuso M, Molnar M J Neurol Sci. 2025; 470:123395.

PMID: 39855013 PMC: 11846688. DOI: 10.1016/j.jns.2025.123395.

An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy.

Slayter J, Casey L, McCullum S, Drost D, Banks A, OConnell C J Rehabil Med. 2025; 57():jrm41254.

PMID: 39810476 PMC: 11748171. DOI: 10.2340/jrm.v57.41254.

References

Talbot K, Tizzano E . The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017; 24(9):529-533. PMC: 5628264. DOI: 10.1038/gt.2017.52. View

Mailman M, Heinz J, Papp A, Snyder P, Sedra M, Wirth B . Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002; 4(1):20-6. DOI: 10.1097/00125817-200201000-00004. View

Mukaka M . Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2013; 24(3):69-71. PMC: 3576830. View

Vazquez-Costa J, Povedano M, Nascimiento-Osorio A, Moreno Escribano A, Garcia S, Dominguez R . Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study. Eur J Neurol. 2022; 29(11):3337-3346. PMC: 9796289. DOI: 10.1111/ene.15501. View

Vazquez-Costa J, Povedano M, Nascimiento-Osorio A, Moreno Escribano A, Garcia S, Dominguez R . Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022; 29(12):3666-3675. PMC: 9826246. DOI: 10.1111/ene.15542. View

Konig K, Pechmann A, Thiele S, Walter M, Schorling D, Tassoni A . De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany. Orphanet J Rare Dis. 2019; 14(1):152. PMC: 6591958. DOI: 10.1186/s13023-019-1125-2. View

Pechmann A, Konig K, Bernert G, Schachtrup K, Schara U, Schorling D . SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019; 14(1):18. PMC: 6341722. DOI: 10.1186/s13023-019-0998-4. View

Sansone V, Walter M, Attarian S, Delstanche S, Mercuri E, Lochmuller H . Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report. J Neuromuscul Dis. 2020; 7(4):523-534. DOI: 10.3233/JND-200534. View

Wadman R, Wijngaarde C, Stam M, Bartels B, Otto L, Lemmink H . Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol. 2017; 25(3):512-518. DOI: 10.1111/ene.13534. View

10.

Kaufmann P, McDermott M, Darras B, Finkel R, Kang P, Oskoui M . Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011; 68(6):779-86. PMC: 3839315. DOI: 10.1001/archneurol.2010.373. View

11.

Wurster C, Koch J, Cordts I, Dreyhaupt J, Otto M, Uzelac Z . Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Front Neurol. 2019; 10:1179. PMC: 6854024. DOI: 10.3389/fneur.2019.01179. View

12.

Kaufmann P, McDermott M, Darras B, Finkel R, Sproule D, Kang P . Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012; 79(18):1889-97. PMC: 3525313. DOI: 10.1212/WNL.0b013e318271f7e4. View

13.

Mercuri E, Darras B, Chiriboga C, Day J, Campbell C, Connolly A . Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018; 378(7):625-635. DOI: 10.1056/NEJMoa1710504. View

14.

Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe M . Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscul Disord. 2014; 24(4):347-52. DOI: 10.1016/j.nmd.2014.01.003. View

15.

Vuillerot C . State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Arch Pediatr. 2020; 27(7S):7S40-7S44. DOI: 10.1016/S0929-693X(20)30276-1. View

16.

Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I . A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997; 146(1):67-72. DOI: 10.1016/s0022-510x(96)00284-5. View

17.

Montes J, McDermott M, Mirek E, Mazzone E, Main M, Glanzman A . Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS One. 2018; 13(6):e0199657. PMC: 6019250. DOI: 10.1371/journal.pone.0199657. View

18.

Gavriilaki M, Moschou M, Papaliagkas V, Notas K, Chatzikyriakou E, Papagiannopoulos S . Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis. Neurotherapeutics. 2022; 19(2):464-475. PMC: 9226250. DOI: 10.1007/s13311-022-01200-3. View

19.

Walter M, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E . Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. J Neuromuscul Dis. 2019; 6(4):453-465. PMC: 6918909. DOI: 10.3233/JND-190416. View

20.

Wijngaarde C, Stam M, Otto L, van Eijk R, Cuppen I, Veldhoen E . Population-based analysis of survival in spinal muscular atrophy. Neurology. 2020; 94(15):e1634-e1644. DOI: 10.1212/WNL.0000000000009248. View